CAR T-CELL THERAPY FOR
MULTIPLE MYELOMA

B-cell maturation antigen (BCMA) is a protein expressed on the surface of virtually all myeloma plasma cells — and importantly, with very limited expression on other cell types. This specificity makes BCMA an ideal target: a CAR recognising BCMA will attack myeloma cells selectively while causing limited damage to other tissues.

“BCMA is expressed on almost every myeloma cell in almost every patient — making it the most reliable target for a cell therapy designed to work across the full myeloma patient population.”

• Why Triple-Class Refractory Disease Needs a New Approach

  A patient who has received a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody, and whose myeloma still progresses, is triple-class refractory. This group faces very limited options. CAR-T therapy uses immune recognition rather than drug mechanism — bypassing the resistance pathways that caused prior treatment failure.

• BCMA Loss: A Known Resistance Mechanism

  A proportion of patients relapsing after BCMA CAR-T show reduced or absent BCMA expression on surviving myeloma cells — antigen loss. This is why next-generation constructs targeting GPRC5D, CD38, or using dual-target approaches are in active development and trial in China.

• Manufacturing: The Same Process as Lymphoma CAR-T

  T cells are collected via leukapheresis, the BCMA-targeting CAR gene is inserted, cells are expanded in a GMP facility over 2-4 weeks, and the product is infused after lymphodepleting chemotherapy. The manufacturing platform is the same; the target is different.

• Functional Cure Potential in Responding Patients

  A subset of patients — particularly those achieving MRD-negative complete response — have remained in sustained remission for years. While durable remission is not guaranteed, the possibility of a prolonged treatment-free period in responding patients is clinically meaningful for a disease historically managed with continuous therapy.

Key BCMA and next-generation CAR-T products — regulatory status and pivotal trial data.

Eligibility requires individual assessment. These are the key clinical factors reviewed before a patient proceeds to CAR-T.

• Prior Treatment Lines

  Approved indications (ide-cel, cilta-cel) require ≥4 prior lines of therapy including a PI, IMiD, and anti-CD38 antibody. Trials may accept patients with fewer prior lines — particularly those who are triple-class refractory regardless of number of lines.

• Performance Status

  ECOG 0-1 is typical; ECOG 2 may be considered at some centres. Patients must be fit enough for lymphodepleting chemotherapy, inpatient monitoring, and the potential toxicity of CRS and ICANS.

• Organ Function

  Adequate renal, hepatic, cardiac, and pulmonary function required. Myeloma commonly causes renal impairment — creatinine clearance thresholds must be met. Prior cardiac amyloid involvement may be an exclusion factor.

• Disease Status and Measurability

  Measurable disease by M-protein, free light chains, or bone marrow plasma cell percentage. Extramedullary disease does not exclude but may affect response rates. Disease must be confirmed as myeloma (not plasma cell leukaemia in some protocols).

From eligibility confirmation to long-term follow-up — what myeloma patients should expect.

1. 1

   Eligibility Assessment and MDT Review

   Haematologist reviews prior treatment lines, cytogenetics (del17p, t(4;14), 1q21 amplification), organ function, performance status, and disease burden. Not all triple-class refractory patients are appropriate candidates.

2. 2

   Leukapheresis — T-Cell Collection

   T cells collected from blood via 3-6 hour apheresis session. Quality of collected cells matters — heavily pre-treated patients or those with very low lymphocyte counts may have manufacturing challenges.

3. 3

   Bridging Therapy

   For patients with active or progressing myeloma during the manufacturing wait, bridging therapy controls disease. Dexamethasone-based regimens or soft-tissue radiation are commonly used.

4. 4

   Lymphodepleting Chemotherapy

   Fludarabine and cyclophosphamide conditioning — typically 3 days, administered as inpatient. Depletes existing immune cells to allow CAR-T expansion.

5. 5

   CAR-T Infusion and Monitoring

   Single IV infusion. Mandatory inpatient monitoring for CRS and ICANS — minimum 7-14 days at the treating centre, often extended. Neurological monitoring is specifically important for BCMA CAR-T products.

6. 6

   Response Assessment

   Serum protein electrophoresis, free light chains, and bone marrow biopsy at approximately 1 and 3 months. MRD testing by next-generation sequencing or flow cytometry for deep response assessment.

China's domestic BCMA CAR-T products provide the most significant cost difference of any therapy category available.

• 97.9%Overall Response Rate — Ciltacabtagene (CARTITUDE-1)78.4% complete response. 34.9 months median PFS — transformative for triple-class refractory disease.
• 96%Overall Response Rate — CT053 FUMANBA-1 (China Phase II)China's domestically approved BCMA CAR-T with Phase III data comparable to Western products.
• 73%Overall Response Rate — Idecabtagene (KarMMa Phase II)33% complete response. First approved BCMA CAR-T — established the proof of concept.
• USD 419KCost of Carvykti in USAvs approximately USD 80,000-150,000 for domestic BCMA CAR-T in China — 70-80% cost reduction.

Explore related CAR-T and myeloma treatment content.

Frequently Asked Questions